This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameCordycepin
Accession NumberDB12156
TypeSmall Molecule
GroupsInvestigational
Description

Cordycepin has been used in trials studying the treatment of Leukemia.

Structure
Thumb
SynonymsNot Available
External IDs NSC-401022 / NSC-63984
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNIIGZ8VF4M2J8
CAS number73-03-0
WeightAverage: 251.2419
Monoisotopic: 251.101839307
Chemical FormulaC10H13N5O3
InChI KeyOFEZSBMBBKLLBJ-BAJZRUMYSA-N
InChI
InChI=1S/C10H13N5O3/c11-8-7-9(13-3-12-8)15(4-14-7)10-6(17)1-5(2-16)18-10/h3-6,10,16-17H,1-2H2,(H2,11,12,13)/t5-,6+,10+/m0/s1
IUPAC Name
(2R,3R,5S)-2-(6-amino-9H-purin-9-yl)-5-(hydroxymethyl)oxolan-3-ol
SMILES
[H][[email protected]@]1(CO)C[[email protected]@]([H])(O)[[email protected]@]([H])(O1)N1C=NC2=C(N)N=CN=C12
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Cordycepin.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Amlodipine.Approved
Amphotericin BThe therapeutic efficacy of Amphotericin B can be decreased when used in combination with Cordycepin.Approved, Investigational
AmrinoneThe risk or severity of adverse effects can be increased when Cordycepin is combined with Amrinone.Approved
AzelnidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Azelnidipine.Approved
AzimilideThe risk or severity of adverse effects can be increased when Cordycepin is combined with Azimilide.Investigational
BarnidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Barnidipine.Approved
BenidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Benidipine.Approved
BepridilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Bepridil.Approved, Withdrawn
BevacizumabBevacizumab may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
BuspironeThe metabolism of Buspirone can be decreased when combined with Cordycepin.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be increased when it is combined with Cordycepin.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Cordycepin.Approved
CarboxyamidotriazoleThe risk or severity of adverse effects can be increased when Cordycepin is combined with Cai.Investigational
CilnidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Cilnidipine.Approved
CinnarizineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Cinnarizine.Approved
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Cordycepin.Approved, Investigational, Withdrawn
ClevidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Clevidipine.Approved
ConivaptanThe metabolism of Conivaptan can be decreased when combined with Cordycepin.Approved, Investigational
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
CyclosporineThe metabolism of Cyclosporine can be decreased when combined with Cordycepin.Approved, Investigational, Vet Approved
DarodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Darodipine.Experimental
DeslanosideDeslanoside may decrease the cardiotoxic activities of Cordycepin.Approved
DidanosineDidanosine can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Cordycepin.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Cordycepin.Approved
DiltiazemThe risk or severity of adverse effects can be increased when Cordycepin is combined with Diltiazem.Approved
DocetaxelThe metabolism of Docetaxel can be decreased when combined with Cordycepin.Approved, Investigational
DofetilideThe metabolism of Dofetilide can be decreased when combined with Cordycepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Dotarizine.Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Efonidipine.Approved
EperisoneThe risk or severity of adverse effects can be increased when Cordycepin is combined with Eperisone.Approved, Investigational
EtravirineThe serum concentration of Etravirine can be increased when it is combined with Cordycepin.Approved
FelodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Felodipine.Approved, Investigational
FendilineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Fendiline.Withdrawn
FlunarizineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Flunarizine.Approved
FosphenytoinThe serum concentration of Cordycepin can be decreased when it is combined with Fosphenytoin.Approved
GabapentinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Gabapentin.Approved, Investigational
GallopamilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Gallopamil.Investigational
IsradipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Isradipine.Approved
LacidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lacidipine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Lercanidipine.Approved, Investigational
LosartanThe metabolism of Losartan can be decreased when combined with Cordycepin.Approved
Magnesium SulfateThe risk or severity of adverse effects can be increased when Cordycepin is combined with Magnesium Sulfate.Approved, Vet Approved
ManidipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Manidipine.Approved
MibefradilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Mibefradil.Withdrawn
NaftopidilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Naftopidil.Investigational
NicardipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nicardipine.Approved
NifedipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nifedipine.Approved
NiguldipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Niguldipine.Experimental
NiludipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Niludipine.Experimental
NilvadipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nilvadipine.Approved
NimesulideThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimesulide.Approved, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Nitrendipine.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Cordycepin.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Cordycepin.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Cordycepin.Approved, Vet Approved
PerhexilineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Perhexiline.Approved
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Cordycepin.Approved, Vet Approved
PimozideCordycepin may increase the arrhythmogenic activities of Pimozide.Approved
PinaveriumThe risk or severity of adverse effects can be increased when Cordycepin is combined with Pinaverium.Approved
PregabalinThe risk or severity of adverse effects can be increased when Cordycepin is combined with Pregabalin.Approved, Illicit, Investigational
PrenylamineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Prenylamine.Withdrawn
ProgesteroneThe therapeutic efficacy of Progesterone can be decreased when used in combination with Cordycepin.Approved, Vet Approved
QuinidineThe metabolism of Quinidine can be decreased when combined with Cordycepin.Approved
RanolazineThe metabolism of Ranolazine can be decreased when combined with Cordycepin.Approved, Investigational
RifabutinThe serum concentration of Rifabutin can be increased when it is combined with Cordycepin.Approved
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Cordycepin.Approved
RifapentineThe serum concentration of Rifapentine can be increased when it is combined with Cordycepin.Approved
RisedronateThe risk or severity of adverse effects can be increased when Cordycepin is combined with Risedronate.Approved, Investigational
SolifenacinThe metabolism of Solifenacin can be decreased when combined with Cordycepin.Approved
SucralfateSucralfate can cause a decrease in the absorption of Cordycepin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SunitinibThe metabolism of Sunitinib can be decreased when combined with Cordycepin.Approved, Investigational
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Cordycepin.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tolfenamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Cordycepin is combined with Tranilast.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Cordycepin.Approved, Investigational
VerapamilThe risk or severity of adverse effects can be increased when Cordycepin is combined with Verapamil.Approved
VinpocetineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Vinpocetine.Investigational
XylometazolineThe risk or severity of adverse effects can be increased when Cordycepin is combined with Xylometazoline.Approved
ZiconotideThe risk or severity of adverse effects can be increased when Cordycepin is combined with Ziconotide.Approved
ZolpidemThe serum concentration of Zolpidem can be increased when it is combined with Cordycepin.Approved
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentLeukemias1
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility11.3 mg/mLALOGPS
logP-0.85ALOGPS
logP-1.4ChemAxon
logS-1.4ALOGPS
pKa (Strongest Acidic)13.53ChemAxon
pKa (Strongest Basic)4.99ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area119.31 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity62.1 m3·mol-1ChemAxon
Polarizability24.15 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted GC-MSPredicted GC-MS Spectrum - GC-MSNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as purine 3'-deoxyribonucleosides. These are compounds consisting of a purine linked to a ribose which lacks a hydroxyl group at position 3.
KingdomChemical entities
Super ClassOrganic compounds
ClassNucleosides, nucleotides, and analogues
Sub ClassPurine nucleosides
Direct ParentPurine 3'-deoxyribonucleosides
Alternative Parents6-aminopurines / Aminopyrimidines and derivatives / Primary aromatic amines / N-substituted imidazoles / Imidolactams / Oxolanes / Heteroaromatic compounds / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds
SubstituentsPurine 3'-deoxyribonucleoside / 6-aminopurine / Imidazopyrimidine / Purine / Aminopyrimidine / N-substituted imidazole / Primary aromatic amine / Pyrimidine / Imidolactam / Heteroaromatic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptorsadenosines, 3'-deoxyribonucleoside (CHEBI:29014 )
Drug created on October 20, 2016 15:29 / Updated on September 01, 2017 12:17